Long-Acting Injectable (LAI) Use in Other CNS Conditions

This meta-analysis found that LAIs are consistently associated with reduced relapse and hospitalization rates versus oral antipsychotics in schizophrenia — driven largely by improved adherence.

Although in a different CNS indication, this high-quality evidence supports the conceptual proof of LAIs improving real-world outcomes by enhancing adherence and reducing relapse, strengthening your argument for LAI in MDD.

Read the full issue